TMDX

TransMedics Group

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$132.7M

Burn Rate (Qtr)

-$5.1M

Company Profile

TransMedics was founded to address the growing need for healthier organs for transplantation. We are focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs.

The Organ Care System (OCS™) platform is a revolutionary technology for preserving organs used in the treatment of end-stage heart, lung, and liver failure.

The OCS is the first and only multi-organ platform to leverage proprietary core technologies across multiple organs.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Organ Care System (OCS™)

Medical Device for Lung Transplant

Quarterly Sales (Approved)

February 2021 (Est)

Organ Care System (OCS™)

Medical Device for Heart Transplant

FDA Advisory Panel Committee Meeting

TBD

Organ Care System (OCS™)

Medical Device for Liver Transplant

TBD

Recent Posts

See what the community is saying - click to see full post

TMDX - TransMedics Reports Third Quarter 2020 Financial Results

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon